Erasca/ERAS

$1.79

-2.71%
-
1D1W1MYTD1YMAX

About Erasca

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.

Ticker

ERAS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jonathan Lim

Employees

126

Headquarters

San diego, United States

Erasca Metrics

BasicAdvanced
$318.94M
Market cap
-
P/E ratio
-$0.83
EPS
-
Beta
-
Dividend rate
$318.94M
$3.38
$1.51
807.6K
12.26
-27.48%
-34.33%
-29.94%
0.878
1.007
57.41%

What the Analysts think about Erasca

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 8 analysts.
318.99% upside
High $11.00
Low $5.00
$1.79
Current price
$7.50
Average price target

Erasca Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-29.7M
-1.98%
Profit margin
0%
-

Erasca Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.95%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.22
-$0.21
-$0.20
-$0.20
-
Expected
-$0.31
-$0.24
-$0.22
-$0.23
-$0.20
Surprise
-29.94%
-11.02%
-9.09%
-11.95%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Erasca stock?

Erasca (ERAS) has a market cap of $318.94M as of April 19, 2024.

What is the P/E ratio for Erasca stock?

The price to earnings (P/E) ratio for Erasca (ERAS) stock is 0 as of April 19, 2024.

Does Erasca stock pay dividends?

No, Erasca (ERAS) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Erasca dividend payment date?

Erasca (ERAS) stock does not pay dividends to its shareholders.

What is the beta indicator for Erasca?

Erasca (ERAS) does not currently have a Beta indicator.

What is the Erasca stock price target?

The target price for Erasca (ERAS) stock is $7.5, which is 318.99% above the current price of $1.79. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Erasca stock

Buy or sell Erasca stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing